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Abstract
HhAntag691 (GDC-0449), a low–molecular weight inhibitor of the tumor-promoting hedgehog (Hh) signaling
pathway, has been used to treat medulloblastoma in animal models and has recently entered clinical trials for a
variety of solid tumors. Here, we show that HhAntag691 inhibits multiple ATP-binding cassette (ABC) transporters.
ATP-binding cassette transporters are within a family of membrane proteins, the overexpression of which is as-
sociated with multidrug resistance, a major impediment to successful cancer treatment. HhAntag691 is a potent
inhibitor of two ABC transporters, ABCG2/BCRP and ABCB1/Pgp, and is a mild inhibitor of ABCC1/MRP1. In
ABCG2-overexpressing HEK293 cells, HhAntag691 increased retention of the fluorescent ABCG2 substrate
BODIPY-prazosin and resensitized these cells to mitoxantrone, an antineoplastic ABCG2 substrate. In Madin-Darby
canine kidney II cells engineered to overexpress Pgp or MRP1, HhAntag691 increased the retention of calcein-AM
and resensitized them to colchicine. HhAntag691 also resensitized human non–small cell lung carcinoma cells
NCI-H460/par and NCI-H460/MX20, which overexpress ABCG2 in response to mitoxantrone, to mitoxantrone,
and to topotecan or SN-38. The IC50 values of HhAntag691 for inhibition of ABCG2 and Pgp were ∼1.4 and
∼3.0 μM, respectively. Because ABC transporters are highly expressed at the blood-brain barrier and on many
tumor cells, they contribute significantly to treatment failure of many types of cancer, particularly of those within
the neuraxis. In addition to its effect on Hh signaling, the ability of HhAntag691 and related compounds to inhibit
two key ABC transporters could contribute to their effectiveness in treating malignancies.
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Introduction
HhAntag691 (GDC-0449) is a low–molecular weight hedgehog (Hh)
pathway inhibitor discovered in a screen searching for compounds tar-
geting the Hh pathway [1]. The Hh pathway is critical for cell growth
and differentiation during embryonic development and is also aber-
rantly activated in a variety of cancers [2]. HhAntag691 is a potent
Hh pathway inhibitor that blocks the function of Smoothened and
has been used successfully to eliminate medulloblastoma in both
Ptc1+/−p53−/− and Cxcr6 mutant mice [1,3]. HhAntag691 is highly ef-
fective, with treatment of only 4 days providing complete tumor re-
gression. Thus, HhAntag691 is a promising anticancer drug and has
entered phase 1 clinical trials along with other Hh pathway inhibitors
such as cyclopamine [2,4]. Cyclopamine, a steroidal alkaloid and less
potent Hh inhibitor, also targets Smoothened and has been found ef-
fective in treating a variety of cancers in tissue culture and animal
models. Cyclopamine enhances the antiproliferative effect of epidermal
growth factor receptor (EGFR) inhibitors in pancreatic cancer cells [5],
depletes glioblastoma stem–like cancer cells in vitro [6], and inhibits
the growth of prostate cancer and medulloblastoma cells [5,7].
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The family of ATP-binding cassette (ABC) proteins is another
important antitumor target [8]. Overexpression of ABC proteins is
associated with multidrug resistance (MDR), a major obstacle for
successful treatment. ATP-binding cassette transporters use the energy
of ATP hydrolysis to export substrates out of cells, thereby reducing
their effective intracellular concentration. The expression of ABC trans-
porters is one mechanism by which cancer cells develop resistance to
chemotherapy. Cancer stem–like cells express ABC transporters that
may contribute to their resistance to therapy and ability to propagate
cancer [9–12]. The Hh pathway has also been found to be up-regulated
in cancer stem–like cells [13,14], to regulate the expression of multiple
ABC transporters including ABCG2/BCRP and ABCB1/Pgp [14],
and to induce ABC transporter–dependent chemoresistance. Agents
that simultaneously inhibit Hh signaling and MDR could greatly im-
prove the efficacy of cancer treatment by targeting cancer stem–like
cells and increasing the intracellular concentration of chemotherapeutic
agents more broadly throughout tumors.
We previously reported that HhAntag691 enhances the bio-
luminescence imaging (BLI) readout in cells expressing firefly lucif-
erase (fLuc), possibly by inhibiting the export of D-luciferin, a
substrate of ABCG2 [15]. In this report, we show that HhAntag691




D-Luciferin sodium salt was obtained from Gold Biotechnology,
Inc. (St. Louis, MO). HhAntag691 was a gift from Infinity Pharma-
ceuticals, Inc. (Cambridge, MA). Verapamil (VP), indomethacin,
colchicine, mitoxantrone, topotecan, SN-38, and calcein-AM were
purchased from Sigma Chemical Company (St Louis, MO). BODIPY-
prazosin was obtained from Invitrogen (Carlsbad, CA). Fumitremorgin
C (FTC) was a kind gift of Dr. S. Bates (National Cancer Insti-
tute, Frederick, MD). All compounds were prepared in DMSO for
in vitro experiments.
Construction of Reporter Plasmid
A CMV promoter–driven fLuc reporter construct carrying a hygro-
mycin B selection marker was generated from pGL4.16[luc2cp/Hygro]
from Promega (Madison, WI). The vector was linearized with NheI,
and a CMV promoter was inserted. The CMV promoter was first
obtained by polymerase chain reaction (PCR) from pCDNA3.1−
CMV-trireporter [16], and an additional NheI site was introduced
by the 5′ primer. The CMV promoter PCR fragment was then
cloned into pCRII-TOPO vector using the TOPO TA cloning kit
(Invitrogen) and cut-out with NheI (PCR primers used: 5′: 5′-GCTA-
GCGAAGAATCTGCTTAGGGTTAGGC-3′, 3′: 5′-CTCGAGGC-
TAGCCAGCTTGGGTCTC-3′). The DNA fragment was purified
with a QIAGEN gel extraction kit (Qiagen, Inc., Valencia, CA) and
was then ligated. CMV− luc2CP/Hygro plasmids were prepared from
transformants from the ligation product, and the orientation of the
promoter inserted was confirmed by NruI and BglII double digestion.
Cell Lines and Transfection
Madin-Darby canine kidney II (MDCKII) cells were cultured in
Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with
10% FBS, and Pgp, MRP1, or ABCG2/MRP2–overexpressing
MDCKII cells [17] were maintained in medium containing 0.8 mg/ml
G418. HEK293 cells were cultured in minimum essential medium
(Invitrogen) supplemented with 10% FBS, and HEK293 cells were
stably transfected with ABCG2-expressing construct, maintained in
medium containing 1 mg/ml G418 [18]. Firefly luciferase-expressing
HEK293 cells were established by transient transfection with CMV-
luc2CP/Hygro, after selection in 50 μg/ml hygromycin B. Transient
transfection was performed with FuGENE6 transfection reagent
(Roche Pharmaceuticals, Nutly, NJ) according to the manufacturer’s
instructions. NCI-H460 human non–small cell lung carcinoma cells
(National Cancer Institute) and NCI-H460/MX20 with ABCG2
overexpression induced by mitoxantrone were established and char-
acterized as described previously [19] and were maintained in RPMI
1640 medium supplemented with 10% FBS and penicillin and
streptomycin. All cultures were maintained at 37°C in a humidified
5% CO2/95% air incubator.
Calcein-AM Uptake Assay
MDCKII cells were plated into 24-well plates at a density of 3 ×
105 cells per well and were allowed to attach. Medium was then
changed to that containing different drugs (50 μM VP, 50 μM indo-
methacin, or 20 μM HhAntag691) in DMSO or DMSO alone as
control, and nonfluorescent calcein-AM was added to a final con-
centration of 1.0 μM and incubated at 37°C for 2 hours. Cells were
then washed twice with Ca2+, Mg2+–containing Hank’s balanced salt
solution buffer and lysed by shaking in 0.01% Triton X-100 in PBS
buffer for 1 hour at room temperature or overnight at 4°C. The
lysate was then transferred into 96-well plates, and the fluorescence
signal caused by the cell-derived calcein was quantified spectrophoto-
metrically with a SpectraMax M5 Multi-Detection Reader (Molecu-
lar Devices Corp., Sunnyvale, CA) using an excitation wavelength of
495 nm and an emission wavelength of 515 nm [20,21]. All manipu-
lations were performed in the dark. All readings are expressed as
mean ± SEM normalized to the control.
BODIPY-Prazosin Uptake Flow Cytometry
ABCG2-overexpressing HEK293 cells were grown in six-well
plates until 70% to 80% confluent. Medium was changed to that
containing 50 μM VP, 5 μM FTC, and 20 μM HhAntag691 or
DMSO only as control. BODIPY-prazosin [18] was added to a final
concentration of 0.25 μM. Cells were incubated at 37°C for 2 hours,
washed with PBS, and harvested. All cells harvested, including those
in the PBS washout, were combined, washed with PBS, and resus-
pended in ice-cold PBS. Analyses were performed with FACScan
(Becton Dickinson, Fullerton, CA) with an excitation wavelength
of 488 nm and an emission wavelength of 530 nm. Ten thousand
events were counted per sample. The resultant histograms were
analyzed with CellQuest software (Becton Dickinson).
Cell Viability Assay
Cell viability was assessed with either an MTT assay [22] or an
XTT assay [23]. When MTT assay was performed, an MTT reagent
was added to each well to a final concentration of 150 μg/ml, and the
cells were incubated for 1 to 2 hours at 37°C. The medium was then
replaced with DMSO to dissolve the reaction product. Absorbance
at 570 nm was quantified using a spectra MAX 340pc plate reader
(Molecular Devices). For the XTT assay, 1 mg/ml XTT (Poly-
sciences, Warrington, PA) was mixed with 0.025 mM PMS (Sigma),
and 50 μl of the mixture was added to each well and incubated for
4 hours at 37°C. After the plates were mixed on a plate shaker,
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absorbance at 450 nm was measured. All results were normalized to a
percentage of absorbance obtained in controls.
Bioluminescence Imaging
Cells were imaged in a medium containing 50 μg/ml D-luciferin and
specific drugs, as indicated. Bioluminescence imaging was performed
with the IVIS 200 small animal imaging system (Xenogen Corp.,
Alameda, CA). Acquisition times varied depending on signal intensity.
Data Analysis
LivingImage (Xenogen Corp.) and IGOR (Wavemetrics, Lake
Oswego, OR) image analysis software were used to superimpose
and analyze the corresponding grayscale photographs and false-color
BLI images. Light intensities of regions of interest were expressed
as total flux (photons/sec). The IC50 values of HhAntag691 as an
inhibitor of ABCG2 and Pgp were calculated using GraphPad Prism
version 4.0 for Windows (GraphPad Software, San Diego, CA),
variable-slope logistic nonlinear regression analysis. Data are presented
as mean ± SEM, n = 3.
Results
HhAntag691 Is a Potent Inhibitor of ABCG2
To test the idea that HhAntag691 is an inhibitor of ABCG2, we
first used an established fluorescent dye uptake assay using BODIPY-
prazosin, a fluorescent ABCG2 substrate. HEK293 cells overexpressing
ABCG2 [18] were incubated with a medium containing BODIPY-
prazosin with or without HhAntag691 or other ABC transporter
inhibitor. Flow cytometry was used to measure the fluorescence re-
tention within the cells. As shown in Figure 1A, compared to con-
trols, HhAntag691 caused a shift of the cell population to higher
fluorescence intensity, similar to that induced by FTC, a specific
and potent ABCG2 inhibitor [24]. Verapamil, a potent Pgp inhibitor
that does not inhibit ABCG2 [8], had no effect. Fumitremorgin C
and HhAntag691 caused 80% and 90% of the cell population, re-
spectively, to shift to higher fluorescence intensity, consistent with
potent ABCG2 inhibition by HhAntag691.
We exploited our recent discovery that D-luciferin, the substrate
of fLuc, is also a substrate of ABCG2 [15], and evaluated the effect
of HhAntag691 on the BLI signal in ABCG2-expressing cells using
D-luciferin as the substrate. FLuc-expressing HEK293/ABCG2 cells
were used for this test. The BLI signal was enhanced by HhAntag691
in a dose-dependent manner (Figure 1B). Owing to the dynamic
change of BLI signal over time [25], data obtained at 40 minutes after
imaging commencement were chosen arbitrarily for analysis, and the
IC50 of HhAntag691 as an ABCG2 inhibitor was calculated to be
∼1.4 μM using variable-slope logistic nonlinear regression analysis.
ABCG2 inhibition by HhAntag691 was further tested in a functional
assay that examines the ability of compounds to reverse ABCG2-
induced drug resistance. Mitoxantrone, an anthracycline antineoplastic
agent and ABCG2 substrate, was chosen for this test [26]. Both
HEK293 cells engineered to overexpress ABCG2 and control cells
carrying an empty vector were incubated for 3 days in medium con-
taining increasing concentrations of mitoxantrone. As expected, the
overexpression of ABCG2 protected cells from mitoxantrone, and
the ABCG2-overexpressing cells survived better than the control
cells at mitoxantrone concentrations ≥0.1 μM. However, the addi-
tion of 10 μM HhAntag691 reversed the protection and reduced
the survival rate of the ABCG2-expressing cells to about the same
level as the control cells (Figure 2). At 5 μM mitoxantrone, 10 μM
HhAntag691 decreased the survival rate from ∼60% in control cells
to ∼39%. In contrast, HhAntag691 had no effect on the sensitivity
of the control parent HEK293 cells to mitoxantrone. These results
confirm that HhAntag691 is indeed an ABCG2 inhibitor and can
increase the effective intracellular concentration of mitoxantrone,
another ABCG2 substrate, through blocking its export.
HhAntag691 Inhibits Pgp and MRP1
To test if HhAntag691 can also inhibit other ABC transporters (Pgp,
MRP1, MRP2) [8], we performed a dye uptake assay using calcein-AM,
a general substrate of ABC transporters [20,21]. MDCKII cells over-
expressing either Pgp, MRP1, or MRP2 [17] were incubated in me-
dium containing calcein-AM with or without HhAntag691. As shown
in Figure 3A, in cells overexpressing Pgp, 20 μM HhAntag691 caused
about the same level of fluorescence retention as 50 μM verapamil, a
potent inhibitor of Pgp, indicating that HhAntag691 is also a potent in-
hibitor of Pgp. HhAntag691 also modestly inhibited MRP1 activity and
had no effect on cells expressing MRP2. The IC50 of HhAntag691
Figure 1. (A) BODIPY-prazosin uptake assay indicates that HhAntag691
is a potent ABCG2/BCRP inhibitor. HEK293 cells overexpressing
ABCG2 were incubated in medium containing 50 μM VP, 5 μM
FTC, 20 μM HhAntag691, or no drug, then BODIPY-prazosin was
added to a final concentration of 0.25 μM, and incubated at
37°C for 2 hours. Cells were then harvested, and subjected to
flow cytometry (excitation wavelength, 488 nm; emission wave-
length, 530 nm). Data were analyzed with CellQuest software.
(B) HhAntag691 causes a dose-dependent increase of biolumines-
cence signal in HEK293/ABCG2 cells expressing fLuc. Cells were
imaged in medium containing 50 μg/mL D-luciferin and increasing
concentrations of HhAntag691, and bioluminescence signal was
quantified. Mean ± SEM, n = 3.
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against Pgp was calculated to be ∼3.0 μM, based on the calcein-AM dye
uptake assay using MDCKII cells overexpressing Pgp (Figure 3B).
HhAntag691 Resensitizes Cells to Colchicine, a Substrate
of Pgp and MRP1
As for the mitoxantrone, a resensitization analysis was performed
using colchicine, a tricyclic alkaloid that is a substrate for both Pgp
and MRP1 [27–29]. Pgp-overexpressing MDCKII cells and control
parent cells were incubated for 3 days in medium containing in-
creasing concentrations of colchicine ±10 μM HhAntag691. Pgp ex-
pression protected MDCKII cells from colchicine, and HhAntag691
(10 μM) resensitized the cells to colchicine as expected for a Pgp
inhibitor (Figure 4). HhAntag691 also resensitized MDCKII cells
overexpressing MRP1 (Figure 4).
HhAntag691 Reverses the Resistance of NCI-H460 Human
Non–Small Cell Lung Carcinoma Cells to Cytotoxic Agents
That Are Substrates of ABCG2
Having proved in cells genetically engineered to overexpress ABC
transporters that HhAntag691 is a potent inhibitor of ABCG2 and
Pgp, we validated the ability of this compound to reverse the drug
resistance in a natural cell line, NCI-H460 human non–small cell lung
carcinoma cells [19]. Parent NCI-H460 cells and NCI-H460/
MX20 cells with mitoxantrone-induced overexpression of ABCG2 were
treated with mitoxantrone and two additional ABCG2 substrates/
chemotherapeutic agents, topotecan [30] and SN-38 [31,32], in
the presence or absence of 10 μM HhAntag691 for 3 days before
their viabilities were assessed using the XTT assay. HhAntag691 re-
versed the resistance of both the parent NCI-H460 cells and the
NCI-H460/MX20 cells to mitoxantrone (Figure 5A) and SN-38
(Figure 5C). HhAntag691 similarly sensitized NCI-H460/MX20 cells
to topotecan (Figure 5B). The extent of resensitization in NCI-H460/
MX20 cells is more than that in NCI-H460/par cells, consistent with
the level of ABCG2 expression in those lines, as characterized previ-
ously by immunoblot analysis [19]. For all three drugs tested, NCI-
H460/MX20 cells survived better than the parent line owing to the
overexpression of ABCG2, but the addition of 10 μM HhAntag691
nullified the protection conferred.
Discussion
We show that HhAntag691, a promising anticancer drug that targets
the tumor-promoting Hh pathway [1], also inhibits ABCG2, Pgp, and
MRP1—important ABC transporters associated with MDR. Our find-
ings raise the possibility that the antitumor effects of HhAntag691
might be related, in part, to the ability of this compound to inhibit
those transporters. As a potent inhibitor of two ABC transporters that
are highly expressed at the blood-brain barrier [33], HhAntag691
should promote passage of certain anticancer drugs across that bar-
rier to ensure effective concentrations within the neuraxis. That
HhAntag691 penetrates the blood-brain barrier well was one of the
reasons it was selected to treat brain tumors [1].
Besides HhAntag691, there are other effective anticancer agents
that are also potent inhibitors of ABC transporters, including the
Figure 2. HhAntag691 resensitizes ABCG2-overexpressing HEK293
cells to mitoxantrone treatment. Cells were plated at a density of
1 × 105 cells per well in a 24-well plate and were allowed to attach
before incubating in medium containing HhAntag691 and/or mito-
xantrone for 3 days. Cell viability was assessed with the MTT assay
and expressed as percentage of control. Mean ± SEM, n = 3.
Figure 3. (A) Fluorescent dye uptake assay indicates that HhAntag691
inhibits Pgp and MRP1 but not MRP2. MDCKII cells overexpressing
Pgp, MRP1, or MRP2 were incubated in medium containing no
drug or different ABC transporter inhibitors (50 μM VP, 50 μM indo-
methacin, or 20 μM HhAntag691), then calcein-AM was added to
a final concentration of 1.0 μM, and incubated at 37°C for 1 hour.
Cells were then washed and lysed, and calcein fluorescence was
determined (excitation wavelength, 495 nm; emission wavelength,
515 nm). All readings are normalized to control when no drug was
added. (B) HhAntag691 causes a dose-dependent increase of fluo-
rescent signal retention of calcein-AM in MDCKII/Pgp cells. Cells
were incubated at 37°C in medium containing 1 μM calcein-AM
and increasing concentrations of HhAntag691 for 2 hours and were
then washed and lysed, and fluorescent signal was quantified (exci-
tation wavelength, 495 nm; emission wavelength, 520 nm). Mean ±
SEM, n = 3.
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tyrosine kinase inhibitors of the EGFR gefitinib [34–36], imatinib
[37], EKI-785, and erlotinib [38]. The possibility has been raised
that modulation of MDR may account for an element of the clinical
effectiveness of those agents [39,40]. Many antiretroviral drugs, such
as lopinavir, nelfinavir, and delavirdine, are also inhibitors of ABCG2,
and it is believed that inhibition of this transporter may have a salutary
effect on the biodistribution of these compounds [41]. ATP-binding
cassette transporters may interact with certain signaling pathways, pro-
viding another mechanism to explain why so many effective anticancer
drugs are also potent inhibitors of ABCG2. For example, Hh pathway
activation induces chemoresistance in an ABC transporter–dependent
manner [14]. Targeting the EGFR and Hh pathways concurrently re-
duced the stem cell–enriched side population, which is characterized
by a high expression of ABCG2 [10,13,42]. Several previous studies
have found that phosphorylation can regulate the function of ABCG2
through affecting its cell surface expression and that EGF treatment
can increase its cell surface expression through the PI3K-Akt signaling
pathway or the MAP kinase cascade [43–46]. That may explain, in part,
why many tyrosine kinase inhibitors also inhibit ABCG2. HhAntag691
may inhibit ABCG2 function through a similar mechanism, but
additional experiments are needed to test if this is indeed the case.
HhAntag691 inhibits both the Hh pathway and ABC transporters,
providing two mechanisms to account for its effectiveness.
The fact that many effective drugs are also potent ABCG2 inhibi-
tors suggests that ABCG2 inhibition contributes to their efficacy and
supports the idea of combining ABCG2 inhibitors with other ther-
apeutics to improve outcome. That is particularly true in the case
of antineoplastic agents, so many of which are known substrates of
MDR pumps, especially ABCG2 [8]. ABCG2 inhibition has not
been evaluated extensively as an adjunct to standard cancer chemo-
therapy, and previous trials evaluating Pgp inhibitors may have been
flawed [47]. HhAntag691, which belongs to a new class of anticancer
drugs just entering clinical trials, may act not only through inhibi-
tion of Hh but also through inhibition of ABCG2. Others have
postulated that targeting Hh might be one way to overcome MDR
[14]—and our data strongly support that contention. We believe that
recognition of this dual action of HhAntag691 (and likely of other
inhibitors of Hh) might make compounds of this class uniquely use-
ful to treat CNS malignancies, where MDR pumps impede access of
chemotherapy to tumor.
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